常山药业
(300255)
| 流通市值：186.02亿 | | | 总市值：186.66亿 |
| 流通股本：9.16亿 | | | 总股本：9.19亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 784,021,902.08 | 567,776,898.46 | 294,318,791.37 | 1,410,439,649.66 |
| 营业收入 | 784,021,902.08 | 567,776,898.46 | 294,318,791.37 | 1,410,439,649.66 |
| 二、营业总成本 | 874,012,625.11 | 639,945,832.06 | 355,149,467.25 | 2,005,215,648.54 |
| 营业成本 | 642,451,312.26 | 477,785,306.22 | 259,321,388.72 | 1,093,062,444.69 |
| 税金及附加 | 7,902,150.2 | 5,778,094.22 | 2,874,375.07 | 21,069,268.5 |
| 销售费用 | 42,991,269.39 | 30,196,731.01 | 17,784,564.85 | 472,844,404.35 |
| 管理费用 | 90,016,432.34 | 60,755,161.79 | 35,926,076.74 | 166,472,603.01 |
| 研发费用 | 23,438,244.55 | 19,285,010.38 | 16,435,989.22 | 158,824,447.18 |
| 财务费用 | 67,213,216.37 | 46,145,528.44 | 22,807,072.65 | 92,942,480.81 |
| 其中:利息费用 | 68,699,138.49 | 46,620,086.92 | 18,896,073.87 | 96,413,978.88 |
| 其中:利息收入 | 2,527,674.79 | 1,664,285.06 | 385,859.98 | 1,841,254.86 |
| 加:投资收益 | - | - | - | 7,024.76 |
| 资产处置收益 | -2,070.63 | -2,070.63 | - | 7,001.33 |
| 资产减值损失(新) | 1,391,537.32 | - | - | -633,317,242.23 |
| 信用减值损失(新) | 531,492.7 | -467,413.11 | -848,407.98 | -25,924,208.51 |
| 其他收益 | 30,589,042.11 | 28,432,853.21 | 2,157,666.48 | 27,678,544.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -57,480,721.53 | -44,205,564.13 | -59,521,417.38 | -1,226,324,879.49 |
| 加:营业外收入 | 34,603,840.21 | 1,169,851.02 | 80,022.13 | 184,165.79 |
| 减:营业外支出 | 2,628,019.53 | 2,516,349.01 | 69,368.34 | 5,554,072.41 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -25,504,900.85 | -45,552,062.12 | -59,510,763.59 | -1,231,694,786.11 |
| 减:所得税费用 | 2,301,122.67 | 1,353,759.18 | 2,495,154.06 | 16,459,329.12 |
| 六、净利润 | -27,806,023.52 | -46,905,821.3 | -62,005,917.65 | -1,248,154,115.23 |
| 持续经营净利润 | -27,806,023.52 | -46,905,821.3 | -62,005,917.65 | -1,248,154,115.23 |
| 归属于母公司股东的净利润 | 7,290,091.73 | -46,902,661.99 | -61,665,097.94 | -1,240,210,952.88 |
| 少数股东损益 | -35,096,115.25 | -3,159.31 | -340,819.71 | -7,943,162.35 |
| (一)基本每股收益 | 0.01 | -0.05 | -0.07 | -1.35 |
| (二)稀释每股收益 | 0.01 | -0.05 | -0.07 | -1.35 |
| 八、其他综合收益 | 2,004.77 | 39,961.99 | -43,398.03 | -1,582,310.32 |
| 归属于母公司股东的其他综合收益 | 2,004.77 | 39,961.99 | -43,398.03 | -1,582,310.32 |
| 九、综合收益总额 | -27,804,018.75 | -46,865,859.31 | -62,049,315.68 | -1,249,736,425.55 |
| 归属于母公司股东的综合收益总额 | 7,292,096.5 | -46,862,700 | -61,708,495.97 | -1,241,793,263.2 |
| 归属于少数股东的综合收益总额 | -35,096,115.25 | -3,159.31 | -340,819.71 | -7,943,162.35 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |